案例报告:成功治疗皮肤肌炎与telitacicept
Xinyu Fu1, Miao Yan1, Yuan Song1
1Department of Nephrology, Renmin Hospital of Wuhan University, Wuhan, China.
Case reports in medicine
|October 22, 2025
概括
一种免疫抑制剂Telitacicept在治疗自身免疫性疾病皮肤肌肉炎方面表现有前途. 一个案例研究表明,在接受telitacicept与常规疗法一起治疗的患者中,显著的临床缓解和降低了类固醇使用.
科学领域:
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
- 皮肤病学 皮肤病学
背景情况:
- 皮质肌炎是一种罕见的自身免疫性疾病,其特征是肌肉炎症和皮肤皮疹.
- 目前的治疗方法包括葡萄糖皮质类药物,免疫球蛋白,甲状腺素和修复剂,这些药物可能会产生显著的副作用.
- 一种新型免疫抑制剂Telitacicept在治疗系统性红斑狼方面表现出有效性.
研究的目的:
- 为了调查telitacicept在治疗皮肤肌炎的潜在疗效.
- 报告一个成功用telitacicept治疗的皮肤肌炎病例.
主要方法:
- 一个65岁的男性患者患有皮肤肌炎的案例研究.
- 传统的治疗与telitacicept疗法相结合.
- 在1年的随访期内对治疗反应进行临床评估和监测.
主要成果:
- 患者实现了显著的皮肤肌炎症状的临床缓解,包括红斑,四肢虚弱和.
- 在telitacicept给药后,甲基普雷迪尼索隆剂量成功降低.
- 在1年的随访后,观察到临床症状的显著改善.
结论:
- 泰利塔西塞普可能是皮肤肌炎的可行和有效的治疗选择.
- 这份病例报告是第一个表明telitacicept在皮肤肌炎治疗中的有效性.
- 需要进一步的研究来探索特利塔西塞普在治疗皮肤肌炎中的作用.
相关概念视频
Tumor Immunotherapy
2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
755
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
755
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
880
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
880
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
692
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
692
Myocarditis III: Medical Management
343
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
343
Pericarditis III: Medical Management
586
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
586
